Maia Biotechnology Stock Alpha and Beta Analysis
| MAIA Stock | USD 2.09 0.01 0.48% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MAIA Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in MAIA Biotechnology over a specified time horizon. Remember, high MAIA Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MAIA Biotechnology's market risk premium analysis include:
Beta 0.8 | Alpha (0.51) | Risk 5.18 | Sharpe Ratio (0.05) | Expected Return (0.27) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
MAIA |
MAIA Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MAIA Biotechnology market risk premium is the additional return an investor will receive from holding MAIA Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MAIA Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MAIA Biotechnology's performance over market.| α | -0.51 | β | 0.80 |
MAIA Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of MAIA Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how MAIA Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.MAIA Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how MAIA Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading MAIA Biotechnology shares will generate the highest return on investment. By understating and applying MAIA Biotechnology stock market price indicators, traders can identify MAIA Biotechnology position entry and exit signals to maximize returns.
MAIA Biotechnology Return and Market Media
The median price of MAIA Biotechnology for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 2.71 with a coefficient of variation of 11.48. The daily time series for the period is distributed with a sample standard deviation of 0.31, arithmetic mean of 2.73, and mean deviation of 0.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | MAIA Biotechnologys Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits | 09/10/2024 |
2 | Acquisition by Guerrero Ramiro of 1200 shares of MAIA Biotechnology at 2.47 subject to Rule 16b-3 | 09/17/2024 |
3 | Acquisition by Theagene Jean-manasse of 7232 shares of MAIA Biotechnology at 2.81 subject to Rule 16b-3 | 09/30/2024 |
4 | Acquisition by Louie Ngar Yee of 13790 shares of MAIA Biotechnology at 2.2 subject to Rule 16b-3 | 10/04/2024 |
5 | MAIA Biotechnology prices 2.44M private placement | 10/29/2024 |
6 | Acquisition by Smith Stan of 100000 shares of MAIA Biotechnology at 2.259 subject to Rule 16b-3 | 11/01/2024 |
7 | Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechnology Inc | 11/05/2024 |
8 | MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks | 11/08/2024 |
9 | Acquisition by Vitoc Vlad of 19982 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3 | 11/15/2024 |
10 | Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat | 11/18/2024 |
About MAIA Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MAIA or other stocks. Alpha measures the amount that position in MAIA Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
MAIA Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of MAIA Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MAIA Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of MAIA Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of MAIA Biotechnology. Please utilize our Beneish M Score to check the likelihood of MAIA Biotechnology's management manipulating its earnings.
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with MAIA Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out MAIA Biotechnology Backtesting, MAIA Biotechnology Valuation, MAIA Biotechnology Correlation, MAIA Biotechnology Hype Analysis, MAIA Biotechnology Volatility, MAIA Biotechnology History and analyze MAIA Biotechnology Performance. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
MAIA Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.